Marcello Rotta

[Marcello Rotta @marcellorottamd]

The Ancient Romans That Healed Through Pleasure - The Atlantic https://t.co/ybAX6zL6LS

[NYT Health @NYTHealth]

Why doctors care about happiness https://t.co/UG0KC8Ft0H

[Anas Younes, M.D. @DrAnasYounes]

FDA Approves Ibrutinib as Initial CLL Treatment https://t.co/gCwB1deRUF

[Blood Journals Portfolio @BloodPortfolio]

How I treat extramedullary #myeloma https://t.co/Hzqwo0c1w6 @CHUnantes

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

NOAC and drug interactions @MedscapeKidney @Medscape #Nephpearls
https://t.co/kUXsmQI6t0

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

NOAC dosing in patients with renal dysfunction from @MedscapeKidney @Medscape #Nephpearls
https://t.co/kUXsmQI6t0

[Muzaffar Qazilbash @Transplant_Doc]

Allogeneic transplantation for multiple myeloma: yes, no or maybe? - PubMed - NCBI https://t.co/A0QxnejZtP

[Tim Fenske @timfenske]

Ibrutinib versus temsirolimus in rel/refr mantle-cell lymphoma: an international, phase 3 study Lancet https://t.co/us89Mtwm0y

[Vincent Rajkumar @VincentRK]

Lets make it clear that every one of them is to b used on clinical trials only. KRd in high risk may be an exception https://t.co/ddGtEHoOnv

[Kevin Pho, M.D. @kevinmd]

An oncologist reflects on his inpatient internal medicine service https://t.co/aGLvYbmjai

[Marcello Rotta @marcellorottamd]

ASCO in training exam today. An humbling experience.

[Krishna Komanduri, MD, FASTCT @drkomanduri]

Anasetti in #BMTTandem16 Donor Smackdown: Nice slide, advantages/disadvantages of competing donor sources. #bmtsm

[Jeff Szer @marrow]

Conclusion slide of the first 3 speakers in Great Debate onsStem cell source. #BMTTandem16

[Jeff Szer @marrow]

Litzow: exciting early results with bispecific T engaging antibodies #BMTTandem16

[Aaron Logan, MD, PhD, MPhil @hemedoc]

#BMTTandem16 Litzow: The bispecific engager platform has huge potential. Many other molecules under study already.

[Mikkael A. Sekeres MD, MS @MikkaelSekeres]

When we become the tools of billing, the patient story degrades to diagnostic codes. https://t.co/BddoYd1WXe

[Muthalagu Ramanathan @MuthalaguMD]

#BMTTandem16 maternal recipient of haplo cells from offspring had higher relapse compared to paternal recipients.

[Marcello Rotta @marcellorottamd]

Fenomenal https://t.co/TIpehhCpVa

[Jeff Szer @marrow]

Kenderian concludes with conclusion that checkpoint inhibitors combined with CAR T cells is logical. #BMTTandem16